Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitochondrial Cocktail in ASD with Mitochondrial Dysfunction
NCT02348125Phase 1Unknown
- Sponsor
- Drexel University
- Start
- Mar 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of coenzyme q10, levocarnitine and alpha-lipoic acid in Autism Spectrum Disorder (ASD) and mitochondrial disease, sponsored by Drexel University. Primary endpoints: Social Responsiveness Scale at 6 months and Behavior Rating Inventory of Executive Function at 6 months. Status: unknown.
02
Drugs
coenzyme q10levocarnitinealpha-lipoic acid
03
Conditions
Autism Spectrum Disorder (ASD)mitochondrial disease
Beyond the preview
Go deeper on NCT02348125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02348125.